Filing Flows › Ardelyx (ARDX) › Guidance & outlook
Ardelyx (ARDX) guidance and outlook
Ardelyx (ARDX) reaffirmed its guidance on Nov 3, 2026: Revenue $350M–$370M for FY2026. Ardelyx's 10-Q filed Nov 3, 2026 makes 6 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $350M–$370M | reaffirmed |
From the earnings release filed Nov 3, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 3, 2026
- Enrollment in ACCEL is now complete and we remain on track to announce topline data in the second half of 2027.
- We believe XPHOZAH can bring meaningful relief to adult CKD patients on dialysis, the vast majority of whom have elevated levels of serum phosphorus and are unable to achieve target serum phosphorus levels with phosphate binders alone.
- We expect that we will increasingly rely on cash generated from our commercial operations to fund our operating plan while maintaining financial flexibility to source cash from future equity sales and debt financing.
- We have based this estimate on assumptions that may prove to be wrong and we could utilize our available capital resources sooner than we currently expect.
- There are no assurances that our efforts to meet our operating cash flow requirements will be successful.
- We have discussed those policies and estimates that we believe are critical and require the use of significant judgment in their application in our 2025 Form 10-K.
Ardelyx's latest quarter
Ardelyx, Q3 2026: revenue $128M (+16% year over year), operating margin 3.2%, net loss $737K, operating cash flow $2.2M. The chart follows the revenue to costs, profit and cash.
Questions
Did Ardelyx raise or lower its guidance?
Ardelyx (ARDX) reaffirmed its guidance on Nov 3, 2026: Revenue $350M–$370M for FY2026.
What does Ardelyx expect?
Enrollment in ACCEL is now complete and we remain on track to announce topline data in the second half of 2027. We believe XPHOZAH can bring meaningful relief to adult CKD patients on dialysis, the vast majority of whom have elevated levels of serum phosphorus and are unable to achieve target serum phosphorus levels with phosphate binders alone. We expect that we will increasingly rely on cash generated from our commercial operations to fund our operating plan while maintaining financial flexibility to source cash from future equity sales and debt financing.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.